Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

NCT00113048 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00113048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00113048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2003
Completion date
September 30, 2005
Enrollment
24
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies